tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Charles Duncan, 472 are a BUY (91.12%), 43 are a HOLD (8.3%), 3 are a SELL (0.58%).
Analyst Charles Duncan, carries an average stock price target met ratio of 46.74% that have a potential upside of 46.31% achieved within 333 days. Previously, Charles Duncan worked at CANTOR FITZGERALD.
Charles Duncan’s has documented 992 price targets and ratings displayed on 76 stocks. The coverage was on Healthcare, Industrials, Technology, Basic Materials sectors.
Most recent stock forecast was given on SLDB, Solid Biosciences LLC at 22-Sep-2025.
Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for RETA (REATA PHARMACEUTICALS) at 7/24/2023. The price target of $145 was fulfilled within 4 days with a profit of $35.33 (32.21%) receiving and performance score of 80.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 25-Mar-2026
$29
$8.25 (39.76%)
6 days ago
(25-Mar-2026)
10/12 (83.33%)
$6.99 (31.76%)
275
Buy Since 10-Oct-2023
$34
$13.25 (63.86%)
$31
27 days ago
(04-Mar-2026)
8/15 (53.33%)
$10.61 (45.36%)
113
Buy Since 23-Jun-2025
$30
$9.25 (44.58%)
$31
1 months 5 days ago
(26-Feb-2026)
0/6 (0%)
$5.36 (21.75%)
Buy Since 07-Aug-2015
$37
$16.25 (78.31%)
$35
1 months 5 days ago
(26-Feb-2026)
6/15 (40%)
$12.36 (50.16%)
739
Hold Since 09-Mar-2021
$24
$3.25 (15.66%)
$25
1 months 5 days ago
(26-Feb-2026)
19/22 (86.36%)
$-0.64 (-2.60%)
121
What Year was the first public recommendation made by Charles Duncan?
